Related Experiment Video

Updated: Jun 5, 2026

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
08:48

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase

Published on: November 5, 2021

Chagas disease: Present status of pathogenic mechanisms and chemotherapy

Juan Diego Maya1, Myriam Orellana, Jorge Ferreira

  • 1Programa de Farmacología Molecular y Clínica, ICBM, Facultad de Medicina, Universidad de Chile, Chile. jmaya@med.uchile.cl

Biological Research
|January 21, 2011
PubMed

Insights

Chagas disease affects millions in Latin America. Aspirin, a cyclooxygenase inhibitor, reduced Trypanosoma cruzi infection and mortality in mice, suggesting potential for chronic Chagas treatment.

Area of Science:

  • Parasitology
  • Tropical Medicine
  • Pharmacology

Background:

  • Chagas disease, caused by Trypanosoma cruzi, impacts 7.8 million people in Latin America, risking severe heart complications.
  • Current treatments for chronic Chagas disease lack complete parasite eradication and are less effective than in the acute phase.
  • Alternative therapeutic strategies are needed to enhance the efficacy of existing anti-Chagasic drugs or modulate the host immune response.

Purpose of the Study:

  • To investigate the potential of cyclooxygenase (COX) inhibitors, specifically aspirin, as an adjunct therapy for Chagas disease.
  • To evaluate the effect of aspirin on Trypanosoma cruzi infection in vitro and in vivo models.
  • To assess the impact of prostaglandin inhibition on Chagasic myocarditis and mortality.

Main Methods:

  • In vitro assessment of aspirin's effect on intracellular Trypanosoma cruzi infection in RAW 264.7 cells.
  • In vivo evaluation of aspirin's efficacy in a mouse model of Chagas disease, measuring myocarditis and mortality rates.
  • Exploration of prostaglandin inhibition as a host-directed therapy for Chagas disease.

Main Results:

  • Aspirin significantly reduced intracellular Trypanosoma cruzi infection in macrophages.
  • Aspirin treatment decreased the extent of myocarditis and lowered mortality rates in infected mice.
  • The study highlights the potential of prostaglandin pathway modulation in managing Chagas disease.

Conclusions:

  • Aspirin demonstrates therapeutic potential in reducing Trypanosoma cruzi infection and mitigating severe outcomes of Chagas disease.
  • Cyclooxygenase inhibition represents a promising avenue for developing novel treatment strategies for chronic Chagas disease.
  • Further research is warranted to determine the long-term benefits and clinical applicability of prostaglandin inhibition in Chagasic patients.

More Related Videos

Demystifying In Vivo Bioluminescence Imaging of a Chagas Disease Mouse Model for Drug Efficacy Studies07:59

Demystifying In Vivo Bioluminescence Imaging of a Chagas Disease Mouse Model for Drug Efficacy Studies

Published on: May 31, 2024

Sexual Transmission of American Trypanosomes from Males and Females to Naive Mates13:55

Sexual Transmission of American Trypanosomes from Males and Females to Naive Mates

Published on: January 27, 2019

Related Concept Videos

American Trypanosomiasis01:22

American Trypanosomiasis

Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Esophageal Achalasia01:27

Esophageal Achalasia

Esophageal achalasia is a chronic neurogenic disorder characterized by impaired relaxation of the lower esophageal sphincter (LES) and absent or ineffective peristalsis in the distal esophagus. This leads to a functional obstruction without a physical blockage, despite significant disruption of esophageal motility.EtiologyAchalasia is caused by degeneration of the myenteric (Auerbach's) plexus, specifically the loss of inhibitory ganglion cells that produce vasoactive intestinal peptide (VIP)...
Malaria01:29

Malaria

Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
Leishmaniasis01:30

Leishmaniasis

Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...